Hikma Pharmaceuticals Share Price (HIK)

1,843.50 +57.00 (+3.19%) delayed: 1:29PM GMT
Bid price 1,843.00 Open price 1,770.50
Ask price 1,843.50 Prev close 1,843.50
High price 1,854.50 Spread 0.03%
Low price 1,763.20 Volume 731,777

Register now for FREE live Hikma Pharmaceuticals share prices, Hikma Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Hikma Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Hikma Pharmaceuticals (HIK) and other London Stock Exchange equities.

Hikma Pharmaceuticals Share Price Chart

Advanced Charts >>

Register now for FREE Hikma Pharmaceuticals share price charts

Hikma Pharmaceuticals Share Price Information

Name Hikma Pharmaceuticals Epic HIK
Sector Pharmaceuticals & Biotechnology ISIN GB00B0LCW083
Activites Hikma Pharmaceuticals plc is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'njectables, Generics and Branded, based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million. Index FTSE 250

Hikma Pharmaceuticals Key Numbers

Latest Share Price (p) 1,843.50 Net Gearing (%) 48.20
Market Capitalisation (£m) 4,313.60 Gross Gearing (%) 54.90
Shares in issue (m) 241.46 Debt Ratio 41.03
P/E Ratio -5.08 Debt-to-Equity Ratio 0.57
Total dividends per share (p) 34.00 Assets / Equity Ratio 2.22
Dividend Yield (%) 1.26 Price to book value 2.82
Dividend cover (x) 0.00 ROCE (%) -28.48
Earning per share (p) -351.80 EPS Growth (%) -629.02
52 week high / low 2,089.00 / 814.20 DPS Growth (%) 3.03

Hikma Pharmaceuticals Director Deals

Dec.Date Type Director Pos No. of Shares
30/05/2018 BUY Sigurdur Olafsson CEO 20,000
23/05/2018 BUY John Castellani NED 1,000
15/05/2018 TIN Mazen Darwazah ED 20,000
15/05/2018 TIN Said Darwazah CH 27,000
19/03/2018 TIN Mazen Darwazah ED 38,501

More Hikma Pharmaceuticals Director Deals >>

Hikma Pharmaceuticals Company News

10:24 10/12/2018

Hikma launches treatment for seizures in patients suffering from Lennox-Gastaut syndrome

Hikma Pharmaceuticals launched Monday its treatment for seizures in patients suffering from Lennox-Gastaut syndrome. Clobazam Oral Suspension, and Clobazam Tablet, the generic equivalent to Onfi, would be among the first generics available on the market, the company said. According to IQVIA,...

09:00 10/12/2018

Hikma launches Clobazam

RNS Number : 8882J Hikma Pharmaceuticals Plc 10 December 2018   London, 10 December 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that Hikma Pharmaceuticals USA Inc.,...

10:30 03/12/2018

Total Voting Rights

RNS Number : 2167J Hikma Pharmaceuticals Plc 03 December 2018     Hikma Pharmaceuticals PLC Total Voting Rights and Capital   LONDON, 3 December 2018 - In accordance with the UK Financial Conduct Authority's (the " FCA ") DTR 5.6.1, Hikma Pharmaceuticals PLC...

More Hikma Pharmaceuticals Company News >>

Register now for FREE Hikma Pharmaceuticals company news

Hikma Pharmaceuticals Share Price Discussions

more than 1 year ago

Hikma Pharmaceuticals (HIK)

Floated in London last November at 290p (FTSE-250). Company website www.hikma.com Develops, manufactures and markets branded and non-branded generic pharmaceuticals, as well as in-licensed, patented pharmaceuticals Geographic markets: USA, Europe and the Middle East & North Africa...

Register now for FREE Hikma Pharmaceuticals share price discussions